Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Analysts

Personalis, Inc. (NASDAQ:PSNL) has received a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have covered the stock in the last year is $7.67.

Several research firms recently weighed in on PSNL. Needham & Company LLC restated a “buy” rating and issued a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. HC Wainwright upped their price objective on Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Finally, Guggenheim started coverage on shares of Personalis in a report on Thursday, May 15th. They set a “buy” rating and a $6.00 price objective on the stock.

Personalis Price Performance

Personalis stock opened at $6.15 on Tuesday. The stock has a market cap of $543.17 million, a price-to-earnings ratio of -4.77 and a beta of 1.95. Personalis has a 1 year low of $2.81 and a 1 year high of $7.79. The firm has a 50-day moving average of $6.00 and a two-hundred day moving average of $4.91.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $20.61 million during the quarter, compared to analysts’ expectations of $17.41 million. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. Research analysts expect that Personalis will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On Personalis

Institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its position in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after buying an additional 2,395 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Personalis by 18.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company’s stock worth $62,000 after purchasing an additional 2,724 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Personalis in the 4th quarter valued at $28,000. Stifel Financial Corp lifted its holdings in Personalis by 25.0% in the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after acquiring an additional 5,654 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.